Clinical trials: Blood
HIV-1 Infected Adults With Chronic HIV-1 Infection
Enhancement by Poly-ICLC During HIV-1 Infection
This study involves researching new approaches to treating HIV infection. Currently, HIV infection is treated with combinations of drugs called antiretrovirals.
- Trial name
- Poly-ICLC (NCT02071095)
- Testing
- Arm A: Poly-ICLC, Arm B: Normal Saline
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nina Bhardwaj
Human Immunodeficiency Virus
Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women
HIV Open-label Prevention Extension (HOPE).
- Trial name
- NCT02858037
- Testing
- Dapivirine Vaginal Ring
- Where
- 17 sites in Malawi, South Africa and 2 more
- Volunteers
- 1,456 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Immune Thrombocytopenia
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
- Trial name
- NCT04638829
- Testing
- Avatrombopag Oral Tablet
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sobi, Inc.
Cerebral Palsy
A Study of UCB and MSCs in Children With CP: ACCeNT-CP
The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal…
- Trial name
- ACCeNT-CP (NCT03473301)
- Testing
- Infusion of allogeneic umbilical cord blood, Infusion of MSCs
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Joanne Kurtzberg, MD
Cardiovascular Disease, Hypertension
Stop Atherosclerosis in Native Diabetics Study
Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness…
- Conditions
- Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes
- Trial name
- SANDS (NCT00147251)
- Testing
- FDA approved drugs to treat blood pressure and cholesterol
- Where
- 4 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Cynthia West
Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance
Using Mirabegron to Increase BP in Patients With POTS
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and…
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
- Trial name
- RAISE-BP (NCT06133075)
- Testing
- Mirabegron 50 MG, Mirabegron 25 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Multiple Myeloma
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
- Trial name
- NCT00103506
- Testing
- Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 646 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infection, Vaginal Atrophy
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
During menopause, there is a decrease in a hormone estrogen, which leads to aging of the vagina. Vaginal aging includes changes in the type and amount of healthy bacteria in the vagina, inflammation and a breakdown of natural…
- Conditions
- HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions
- Trial name
- NCT04079218
- Testing
- Estradiol Vaginal Insert
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kerry Murphy
HIV Infections
Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
The purpose of this study was to evaluate the safety and tolerability of ruxolitinib in HIV-positive adults who were virologically suppressed and who were on antiretroviral therapy (ART).
- Trial name
- NCT02475655
- Testing
- Ruxolitinib
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and…
- Trial name
- NCT02465515
- Testing
- Albiglutide 30 mg, Albiglutide 50 mg
- Where
- 607 sites in United States, Argentina and 26 more
- Volunteers
- 9,463 people
- Sponsor
- GlaxoSmithKline
Effects of High Altitude, Hypoxia
Induced Changes in Ventilatory Responsiveness and Altitude Exposure
The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can increase the amount of oxygen in your body at a high altitude of 11,500 feet.
- Conditions
- Effects of High Altitude, Hypoxia, Inadequate or Impaired Breathing Pattern or Ventilation, Abnormal Blood Oxygen Pressure
- Trial name
- NCT01241513
- Testing
- NAC
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- United States Army Research Institute of Environmental Medicine
Human Immunodeficiency Virus 1
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
The purpose of this study is to compare change of brachial artery flow mediated vasodilatation using Darunavir/Ritonavir (DRV/r) 800/100 mg once daily as a monotherapy (use of a single medication) versus a triple combination…
- Trial name
- MONARCH (NCT01391013)
- Testing
- Darunavir(DRV), Ritonavir, 2 nucleoside reverse transcriptase inhibitors (NRTIs)
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag S.p.A.
Multiple Myeloma
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
The study drug elotuzumab, has been clinically shown to be effective in treating relapsed/refractory MM in combination with either bortezomib, or lenalidomide and dexamethasone.
- Trial name
- NCT03361306
- Testing
- Elotuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Type2 Diabetes Mellitus
Basal Insulin Strategies Before Surgery
Many patients with Type 2 Diabetes Mellitus (T2DM) are currently being managed with Basal Insulin (BI). However, there is little evidence to support guidelines on dosing adjustments in the preoperative period.
- Trial name
- NCT03104738
- Testing
- 25% reduction of basal insulin dose
- Volunteers
- 40 people
- Sponsor
- Ohio State University
Hiv, HIV Infections
Standardized Patients to Measure and Address Intersectional Stigma
This study aims to develop and evaluate an intervention to reduce enacted stigma in healthcare settings aimed at people living with HIV (PLWH) and men who have sex with men (MSM) in China.
- Conditions
- Hiv, HIV Infections, AIDS
- Trial name
- NCT04896216
- Testing
- Stigma Reduction Intervention
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Minnesota
Hypertension
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood…
- Trial name
- BP CRUSH (NCT00791258)
- Testing
- amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
- Where
- 72 sites in United States
- Volunteers
- 999 people
- Sponsor
- Daiichi Sankyo
HIV Dementia, HIV-Associated Cognitive Motor Complex
Intranasal Insulin for the Treatment of HAND
Infection with HIV (the virus that causes AIDS) can lead to problems with brain function, such as memory, concentration, judgment, and the speed or control of hands and legs.
- Trial name
- NCT03081117
- Testing
- Insulin, intranasal
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Johns Hopkins University
Multiple Myeloma
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Multiple myeloma (MM) is a common incurable blood cancer causing debilitating symptoms-bone pain, kidney failure, low blood counts and infection.
- Trial name
- NCT02331368
- Testing
- Autologous Stem Cell Transplant, Melphalan, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.